Ten years after the debut of revolutionary new cures for hepatitis C, as countries around the world eliminate the disease, the U.S. has made no progress. My home state of New Mexico is struggling against the epidemic harder than most. For The New York Times: nytimes.com/2024/04/28/hea…

Thanks to AJG - The American Journal of Gastroenterology for the opportunity to write this piece on alcohol associated liver disease with my colleagues. Michigan Hepatology Anne Fernandez #livertwitter

HCV treatment via telemedicine integrated with addiction care.

92% DAA initiation.

ITT cure rate of 90% with telemed vs 39% usual care. Population - people with opioid use disorder. Trial was pragmatic.

Programs like these should be implemented WIDELY
bit.ly/3TCfxHa

Out now 💥 pragmatic RCT which found higher HCV cure rates with facilitated telemedicine integrated into opioid treatment programs led by Dr. Andrew Talal at UBuffalo. Proud to be part of this study. Michigan Hepatology MountSinaiLiver #livertwitter

There is no safe amount of alcohol in cirrhosis

Even “non-alcoholic” cirrhosis

But most people drink every week

many never receive any guidance or intervention from their doctor

Let’s change that

Author: Jeremy Louissaint
In: Hepatology Communications
journals.lww.com/hepcomm/fullte…

Team 144 💛💙 #leavenothingtakeeverything #GoBlue

Genius 💛💙. Always and forever #GoBlue

#PublicHealth Partners: Add the #HepatitisC treatment locator widget to your website to help patients find #HepC treatment: bit.ly/3I2DQcg

“It’s no longer an opioid epidemic… This is an addiction crisis” Cara Poland great piece highlighting so much more work needed to be done via The New York Times nytimes.com/2023/11/13/hea…

REACH is at AASLD #LM @# with posters on utilizing telehealth for HCV care and treatment among people who use drugs!

Thanks renumathyd definitely a highlight for me as well. Thanks again for all that you did to bring us together during COVID.

Celebrating an awesome year of activities organized by the AASLD #HepC Special Interest Group (SIG) at the SIG Leader Reception at #TLM23 #endcancer #Livertwitter #IDTwitter #GITwitter CDC Hepatitis HHS_ViralHep #HepatitisElimination

I am excited to be working with you, Harrys Torres, Dr. Jennifer Price and the entire HCV SIG AASLD #TLM2023

Steatotic - fatty - liver disease is a biomarker of many behavioral and social determinants of health

Determinants we have the power to change #tlm23 Naudia Jonassaint

Hey U-M IHPI members: Check your email for an invitation to apply for our next Impact Accelerator program, a boot camp next spring to help you learn communications & policy skills.

Details: ihpi.umich.edu/impact-acceler…

Melissa Creary, PhD, MPH Daphna Stroumsa, MD Nora Becker Ponni Perumalswami

Thanks for sharing, Lizzie Aby, MD! Steps in care that patients with ALD take including GI/liver clinic are important places to think about how we can optimize care. #livertwitter

Next stop Barbie movie! #luckytoworkwiththesewomen